medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Development of a Conceptual Model of Childhood Asthma to Inform Asthma Prevention Policies

Amin Adibi, MSc[1]; Stuart E Turvey, MBBS, DPhil[6]; Tae Yoon Lee, MSc[1]; Malcolm R Sears, MB, ChB[3]; Allen B Becker, MD[4]; Piush J Mandhane, MD[5]; Theo J Moraes, MD, PhD[2]; Padmaja Subbarao, MD[2]; Mohsen Sadatsafavi, MD, PhD[1]

Affiliations:

[1] Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia

[2] The Hospital for Sick Children, Toronto, Ontario, Canada.

[3] Division of Respirology, Department of Medicine, McMaster University

[4] Section of Allergy and Clinical Immunology
Department of Pediatrics and Child Health, University of Manitoba

[5] Faculty of Medicine & Dentistry, Pediatrics Department, University of Alberta

[6] Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of British Columbia and Brotosh Columbia's Children's Hospital

Corresponding author: Mohsen Sadatsafavi
Associate Professor, Faculty of Pharmaceutical Sciences
Centre for Heart Lung Innovation & Dept of Medicine (Respirology)
University of British Columbia
Email: msafavi@mail.ubc.ca

Contribution Statement: MS, SET, and PS conceived the study. MS, SET, PS, and AA drafted the initial concept map as the steering committee. SET, PS, MRS, ABB, PJM, and TM were the members of the Delphi panel and provided structured feedback in two rounds of surveys and the consensus meeting. AA and MS designed the survey. AA analyzed the data, conducted the systematic review, and drafted the manuscript. TYL contributed to the systematic review. All authors revised the manuscript critically and approved the final version to be published.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Background: There is no cure for asthma and as such, prevention remains a major goal. Given budget constraints, the value-for-money proposition of any asthma prevention strategy should be rigorously investigated before its widespread adoption, a task that is often performed through the use of decision-analytic models. The objective of this study was to solicit expert opinion to develop a concept map for a primary prevention policy model for asthma.

Methods: We reviewed currently available decision-analytic models for asthma prevention. A steering committee of economic modelers, allergists and respirologists was then convened to draft a conceptual model of pediatric asthma. A modified Delphi method was followed to refine the conceptual model and achieve consensus among panel experts.

Results: In the final conceptual model, asthma diagnosis was based upon lung function, atopy, and their symptoms, which in turn were affected by patient characteristics (sex, birth mode, ethnicity, lung growth, anthropometrics, rate of weight gain, genetics, and microbiome), family history, and environmental factors (breastfeeding, family/day-care size, pets, season, built environment, socio-economic status, diet, infection, and exposures).

Conclusions: The conceptual model can inform the development and validation of a policy model for childhood asthma prevention.

Keywords: conceptual model; childhood asthma; literature review; economic modelling; Delphi panel

Funding: Genome Canada Large-Scale Applied Research Project

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Background

Asthma remains a major cause of morbidity and economic burden across the globe. Asthma is the leading cause of absence from school and the third leading cause of productivity loss.[1–3] We have estimated the 20-year burden of uncontrolled asthma at $960B in the US, with more than $300B in direct costs alone.[4] There is no cure for asthma and underdiagnosis in children might lead to permanent lung damage due to tissue remodeling[5].

The Canadian Healthy Infant Longitudinal Development Study (CHILD)[6], an ongoing multiethnic birth cohort of 3,455 families launched in 2008, provides an unprecedented opportunity to explore biological and environmental factors that can potentially be modified in early life to prevent asthma. The CHILD team and other investigators have identified antibiotic use, formula feeding, and exposure to phthalates as three modifiable early-life risk factors that can predict asthma diagnosis at the age of five.[7–14] Emerging evidence suggests a causal relationship between these factors, one that is potentially mediated through either microbiome, immune system, or possibly both.[7–10]

Translation of such knowledge into practice, be it guideline recommendations for risk factor modification or policy-level decisions such as rolling out screening programs, will require careful evaluation of the value of any proposed intervention, which can be quantified in terms of the amount of resources that such interventions consume to produce one unit of health gain. Computer models are an indispensable part of such projections, as long-term outcomes of preventive strategies depend on a tangled network of clinical, economic, and behavioral decisions and factors. These models collect evidence from multiple sources and enable projection of intermediate outcomes (e.g., to what extent an antibiotic stewardship program will reduce the risk of asthma) to policy-relevant metrics (e.g., costs and Quality-Adjusted Life Years). In doing so they enable extrapolation beyond the typically short follow-up period of empirical studies to the longer time horizon that is required for properly capturing all the relevant consequences of a policy decision. For these reasons, the use of computer models for policymaking in health is considered "an unavoidable fact of life".[15]

Conventionally, researchers develop a new decision-analytic model for each specific policy question at hand. However, this fragmented approach is inefficient and leads to unnecessary repetition of model development by many research groups, often with inconsistent assumptions.[16] This inconsistency makes it hard to compare the results of similar studies. Lack of transparency that comes with insufficient documentation of such *de novo* models makes scientific replication difficult, and ultimately affects the credibility of projections.[17] Our systematic review of decision-analytic models for asthma interventions concluded that currently-available models lack the granularity

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

needed to inform policy on personalized, risk-prediction-based strategies.[18] An alternative to such *de novo* modeling approach is to decouple the model development process from the policy question, thus creating 'reference models' that can be used to address multiple policy questions within a unified framework.[16] This not only increases the consistency across different policy decisions but also enables proper consideration of 'interactions' among these decisions. For example, large-scale risk-factor modification attempts for asthma (e.g., reduction in exposure to antibiotics) will change the prevalence of asthma, which in turn affects the yield and cost-effectiveness of pediatric asthma screening programs. Reference models can account for these complex interactions.

As the CHILD study and other global initiatives identify more preventive targets for childhood asthma, we recognize the need for a reference decision-analytic model to evaluate long-term effects of these prevention strategies. Here, we review models focused on the primary prevention of asthma and report the formal process through which an expert panel of CHILD study investigators discussed and drafted the concept map for an asthma policy model that reflects the current state of our knowledge about asthma diagnosis.

Methods

The ISPOR-SMDM Modeling Good Research Practices Task Force has advocated for an explicit process of consulting experts and engaging with stakeholders to convert the problem into the appropriate model structure using influence diagrams and concept maps.[19] We followed these steps, starting from a scoping review of decision-analytic models of interventions related to primary prevention of asthma to identify any potential models that can be adapted for evaluating asthma prevention strategies in Canada. This was followed by a formal process of consensus building on both the decision problems that the model will have to tackle and the conceptual structure of such a model in terms of the important domains and associations that need to be considered. The final outcome of this exercise was a concept map of an asthma prevention policy model that could guide the subsequent steps of model development.

Scoping Review

Medline was searched with a combination of MeSH terms *asthma, economic models, cost-benefit analysis, primary prevention,* and *decision support techniques* (details in Appendix I). The search was limited to articles published in English between 2000 to 2020 to reflect recent changes both in our understanding of asthma and the prevalence trends. Abstracts were screened by two of us (TYL and AA), and full texts were reviewed by one of us (AA) to identify the relevance of the study to the context of asthma prevention and to extract the main features of models used for cost-effectiveness analysis.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Steering Group and Delphi Panel

We solicited expert opinion on the conceptual relation of early-life factors that lead to asthma through a modified Delphi process. The Delphi process is an established method for achieving consensus among subject experts that encourages equal participation of the panel members through multiple rounds of surveys or interviews[20,21] The modified Delphi method that was adopted here involved two rounds of an online survey and a final meeting. Participants had a chance to review and reflect on anonymized survey responses from the first round, before responding to the same questions in the second round. A final meeting was then convened to resolve any remaining disagreements and achieve full consensus, similar to the method previously used for the conceptualization of other health economic models.[22]

A steering group consisting of two economic modelers, an allergist, and two respirologists drafted an initial concept map of childhood asthma, based on the risk factors that the clinical experts deemed relevant in one of the following domains: a risk factor for asthma (e.g., family history), a marker of disease progression (e.g., lung function), or a phenotypic presentation that would affect the likelihood of diagnosis (e.g., symptoms). The first draft of the concept map was based on the findings of the scoping review, but the concept map was expanded to incorporate domains identified by the expert panel. The postulated direction of associations between domains (e.g., lung function affecting symptoms) were identified. We then formed a broader expert panel consisting of six academic clinicians and followed the modified Delphi methodology to refine the concept map and achieve consensus among subject experts.

In the first round of the survey, the participants were asked to 1) evaluate the draft concept map and provide feedback on any missing domain, 2) decide on the direction of associations, 3) rank the strength of each relationship, and 4) suggest candidate (bio) markers for each domain (details in Appendix II). As recommended, problem and model conceptualization were formulated irrespectively of data availability (that is, factors that need to be modeled should be considered, no matter if there is empirical evidence to populate the model).[19] In the second round, participants were provided aggregate results of the first round of the survey and asked to answer the same questions after reflecting on their colleagues' opinions and comments. Results of the second-round survey were shared with panel experts before a final virtual meeting and were discussed to achieve full consensus and finalize the concept map. The surveys were conducted online using Qualtrics and analyzed in Tableau v2020.

Role of Funding Agencies

The funding agency did not have a role in the design and analysis of this study.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

RESULTS

Scoping Review

Our search strategy resulted in 11 indexed abstracts published between 2000 to 2020. We reviewed the abstracts and excluded 5 citations for not including a decision mode (n=4), and a language other than English (n=1). The remaining citations (n=6) were fully reviewed. Of these, two were excluded for not targeting asthma prevention as the primary outcome. The remaining 4 studies were included in the analysis. ***Figure 1*** shows the flow of the studies in the scoping review. ***Table 1*** summarizes the included studies. All identified models were simple decision-trees or Markov models designed to address the specific question at hand, often cost-effectiveness of a single intervention.[23–26]

We identified only one publication focused on the conceptualization of an asthma prevention model. Ramos and colleagues reported structuring and validating of a cost-effectiveness model of primary asthma prevention through allergen avoidance.[25] The authors developed the structure of the model through round-tables and validated it via further discussions with experts and comparison to other asthma models.

We did not identify any microsimulation or reference models for the primary prevention of pediatric asthma. Our conclusion from the scoping review was that none of the previous models can be adapted to act as a reference policy model for childhood asthma prevention.

Conceptualization of the Decision Problem

Discussions among experts led to the decision problem framework shown in ***Table 2***. The panel decided that the objective of the policy model should be to evaluate the cost-effectiveness of asthma prevention strategies in the pediatric population living in urban and rural settings in Canada. Outcomes of interest were the incidence and prevalence of asthma, asthma-related hospital admissions, direct and indirect costs, and quality-adjusted life-years (QALYs) for patients and their caregivers from a societal perspective. The group decided not to model constrained resources such as access to specialist physicians at this time. An example policy that the model should be able to evaluate would be the use of risk screening tools to identify children at high risk of asthma and modulating gut microbiome to prevent asthma among high risk individuals. Another example would be the implementation of a national antibiotic stewardship program towards reducing unnecessary antibiotic exposure in children, thus reducing the risk of asthma.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

The target of this consensus making exercise was to conceptualize the natural history of asthma up to diagnosis, as the natural history after diagnosis has been extensively modeled in the literature, as shown in our previous systematic review.[18]

Conceptualization of the Model

The initial draft of the concept map which was developed by the steering group related asthma diagnosis to biological sex, ethnicity, environment, genetics, birth mode, breastfeeding, and infections. The effects were considered to be modulated through lung function, atopy, and possibly microbiome, as shown in ***Figure 2A***.

The Delphi panel refined the draft concept map through two rounds of surveys and a final consensus meeting. Results of the survey are summarized in Appendix III. The panel added additional factors, renamed some factors for clarity, and clustered all factors under three domains of 'patient characteristic', 'family history', and 'environmental factors'. The panel reviewed the direction of causality, assigned strength of relationship to each line in the concept map, as shown in ***Figure 2B***. The final concept map also indicates that the likelihood of a diagnosis of asthma in a child is influenced by multiple factors, namely respiratory symptoms, lung function, and atopy. The panel also proposed potential measures for clinical concepts, as shown in ***Table 3.***

It was decided that the unit of representation in the model will be individual subjects, followed from their date of birth. Given the multidimensionality of risk factors, the team recommended a discrete event simulation model. This approach was deemed particularly advantageous for building a reference model, given its ability captures complex interactions among decisions. Further, the team recommended that the model should follow an open population, due to the importance of modeling realistic aspects of rolling out an intervention or policy, such as the phased implementation of a national screening program. Given the open population nature of the model, the time horizon would be on the calendar year, instead of up to a certain patient age commonly used in previous studies. The team also decided that the model should be open-source and easily accessible to the wider research community.

DISCUSSION

Economic evaluation of asthma prevention interventions is timely, particularly because of the recent identification of early life exposures that might be causally related to asthma diagnosis later in life. Any asthma prevention strategy would require either population-level or individual-level modification of early-life risk factors that impact the disease.[27] Recognized risk factors range from those that might be modifiable at the patient-level (e.g. birth mode, breast-feeding, diet, pets, antibiotics, tobacco), those that might be modifiable but require change at the societal level (e.g.,

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

air pollution, socio-economic status), and those that cannot be modified (e.g. biological sex, family history, genetics). Some strategies, such as reducing unnecessary antibiotics exposure, can – and perhaps should – be adopted across the board. Other potential preventative interventions (such as modification of the microbiome) may be more suitable for high risk individuals given their cost and possible side-effects.

For clinicians, the decision problem is two-fold: who is at high risk for developing asthma and what intervention has the highest preventive potential for the individual? At the societal level and from the perspective of the health-care system, the question becomes what is the most cost-effective combination of screening and risk-reduction strategies for asthma prevention. Our ultimate aim is to develop a modeling platform for the evaluation of the value-for-money potential of such interventions and policies in a unified framework. Here, we solicited expert opinion and developed a concept map for a reference model that can assess the cost-effectiveness of any combination of risk prediction and prevention strategies.

The ISPOR-SMDM task force highlights the risk of payer's influence on the analysis.[19] However, our model is not at risk of such bias given that it is an independently funded reference model designed to address a variety of policy questions. By decoupling model development from any particular policy question, we have eliminated the risk of adopting biased assumptions that may favor the sponsor's outcome of interest.[28] Further, the open-source and accessible nature of the model will facilitate independent evaluation and validation of the model.

Our systematic review of primary prevention models for asthma identified one model conceptualization[25] and 3 modeling publications;[23,24,26] all four were Markov or decision-tree models that modeled a single preventative intervention as a lump-sum reduction in the probability of asthma diagnosis. None modeled the underlying disease processes. In contrast, our conceptual model is based on the progression of personal and environmental risk factors, as well as atopy, lung function, and symptoms over time. Our model structure also accounts for the interplay between these factors such as modification of lifestyle and environmental risk factors in response to worsening symptoms.

This level of granularity allows for developing reference microsimulation models that can evaluate cost-effectiveness analysis of a wide range of screening and intervention methods. For example, our model can be used to inform the design features of a hypothetical asthma risk prediction score, including what target area-under-the-curve (AUC) statistic of the receiver operating characteristic (ROC) curve is good enough for the asthma risk prediction score, or whether the inclusion of additional variables, such as the metagenome and epigenetic deep phenotyping, is a cost-effective enhancement of the risk prediction model.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

CONCLUSIONS

We have followed a formal procedure to solicit expert opinion and draft a concept map for an asthma prevention model. The conceptual model will form the basis for the development and validation of a microsimulation policy model for childhood asthma prevention.

ACKNOWLEDGMENTS

We would like to thank Respiratory Evaluation Sciences Program team at the University of British Columbia for their input and feedback and Zahra Jalali for helping with the graphics.



Figure 1 Flow of analysis for the systematic review

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2 Initial (A) and final (B) concept maps for asthma diagnosis

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 1 Summary of scoping review of primary prevention modeling studies for asthma

Study	Model	Time-horizon	Perspective	Population	Intervention	Comparator
Yieh (2019)[23]	Decision-tree	Birth to age 18	Healthcare and societal	Offspring of pregnant smokers	Vitamin C supplement	Standard prenatal vitamin
Ditkowsky (2017)[24]	Markov	Birth to age 20	Societal	US population	Varicella Vaccination	No universal varicella vaccination
Ramos (2014)[26]	Decision-tree	Birth to age 6	Healthcare system	Unborn children	Uni and multi-faceted primary prevention	Usual care
Ramos (2011)[25]	Decision-tree	Birth to age 6	Healthcare system	Unborn children	Uni and multi-faceted primary prevention	Usual care

Table 2 Objectives, scope, and policy context of primary prevention model of asthma in children

Framework Aspect	Details
Policy context	To evaluate cost-effectiveness of asthma prevention strategies
Funding source	Genome Canada
Disease	Childhood asthma
Perspective	Societal
Target population	Pediatric population in urban and rural settings of Canada
Health outcomes	Incidence and prevalence of asthma, asthma-related admissions, and QALY effects on care-givers
Strategies/comparators	Current standard of care vs asthma risk screening tool (early diagnosis) with any combination of preventative strategies (e.g. modulating gut microbiome, reducing unnecessary antibiotics/phthalate exposure)
Cost(s)	Costs from a societal perspective
Time-Horizon	2025-2045

Table 3 Proposed markers of the disease

Concept	Measures
Lung Function	Normalized spirometry measure, bronchoprovocation measures, Reversibility
Atopy	Immune trajectory, aeroallergen/food through in-vivo or in-vitro testing
Atopy Symptoms	Allergic rhinoconjunctivitis, atopic dermatitis, allergic rhinitis, food allergy
Respiratory Symptoms	Wheeze, cough, episodic shortness of breath

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

REFERENCES

1 The Global Asthma Report 2018. http://www.globalasthmareport.org/ (accessed Aug 24, 2020).

2 To T, Dell S, Dick P, Cicutto L. The burden of illness experienced by young children associated with asthma: a population-based cohort study. *J Asthma Off J Assoc Care Asthma* 2008; **45**: 45–9.

3 Ismaila AS, Sayani AP, Marin M, Su Z. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. *BMC Pulm Med* 2013; **13**: 70.

4 Yaghoubi M, Adibi A, Safari A, FitzGerald JM, Sadatsafavi M. The Projected Economic and Health Burden of Uncontrolled Asthma in the United States. *Am J Respir Crit Care Med* 2019; published online June 5. DOI:10.1164/rccm.201901-0016OC.

5 Sears MR, Greene JM, Willan AR, *et al.* A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. *N Engl J Med* 2003; **349**: 1414–22.

6 Subbarao P, Anand SS, Becker AB, *et al.* The Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining developmental origins of allergy and asthma. *Thorax* 2015; **70**: 998–1000.

7 Patrick DM, Sbihi H, Dai DLY, *et al.* Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies. *Lancet Respir Med* 2020; **0**. DOI:10.1016/S2213-2600(20)30052-7.

8 Boutin RCT, Sbihi H, Dsouza M, *et al.* Mining the infant gut microbiota for therapeutic targets against atopic disease. *Allergy* 2020; **75**. DOI:10.1111/all.14244.

9 Navaranjan G, Takaro TK, Wheeler AJ, *et al.* Early life exposure to phthalates in the Canadian Healthy Infant Longitudinal Development (CHILD) study: a multi-city birth cohort. *J Expo Sci Environ Epidemiol* 2020; **30**: 70–85.

10 Moossavi S, Fehr K, Derakhshani H, *et al.* Human milk fungi: environmental determinants and inter-kingdom associations with milk bacteria in the CHILD Cohort Study. *BMC Microbiol* 2020; **20**: 146.

11 Waser M, Michels KB, Bieli C, *et al.* Inverse association of farm milk consumption with asthma and allergy in rural and suburban populations across Europe. *Clin Exp Allergy J Br Soc Allergy Clin Immunol* 2007; **37**: 661–70.

12 Walker WA, Iyengar RS. Breast milk, microbiota, and intestinal immune homeostasis. *Pediatr Res* 2015; **77**: 220–8.

13 Kuo C-H, Kuo H-F, Huang C-H, Yang S-N, Lee M-S, Hung C-H. Early life exposure to antibiotics and the risk of childhood allergic diseases: an update from the perspective of the hygiene hypothesis. *J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi* 2013; **46**: 320–9.

14 Kozyrskyj AL, Ernst P, Becker AB. Increased risk of childhood asthma from antibiotic use in early life. *Chest* 2007; **131**: 1753–9.

15 Buxton MJ, Drummond MF, Van Hout BA, *et al.* Modelling in economic evaluation: an unavoidable fact of life. *Health Econ* 1997; **6**: 217–27.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.15.20248275; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

16 Afzali HHA, Karnon J, Merlin T. Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions: A Methodological Framework for the Development of Reference Models. *Med Decis Making* 2013; **33**: 325–32.

17 Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R, Tappenden J. Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. *Value Health* 2013; **16**: 542–53.

18 Ehteshami-Afshar S, Zafari Z, Hamidi N, FitzGerald JM, Lynd L, Sadatsafavi M. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions. *Value Health* 2019; **22**: 1070–82.

19 Roberts M, Russell LB, Paltiel AD, *et al.* Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. *Med Decis Mak Int J Soc Med Decis Mak* 2012; **32**: 678–89.

20 Hsu C-C, Sandford B. The Delphi Technique: Making Sense of Consensus. 2007. DOI:10.7275/PDZ9-TH90.

21 Dalkey N, Helmer O. An Experimental Application of the Delphi Method to the Use of Experts. *Manag Sci* 1963; **9**: 458–67.

22 Tabberer M, Gonzalez-McQuire S, Muellerova H, *et al.* Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. *Med Decis Mak Int J Soc Med Decis Mak* 2017; **37**: 440–52.

23 Yieh L, McEvoy CT, Hoffman SW, Caughey AB, MacDonald KD, Dukhovny D. Cost effectiveness of vitamin c supplementation for pregnant smokers to improve offspring lung function at birth and reduce childhood wheeze/asthma. *J Perinatol Off J Calif Perinat Assoc* 2018; **38**: 820–7.

24 Ditkowsky J, Kohlhoff S, Smith-Norowitz TA. The Cost-effectiveness of Varicella Zoster Virus Vaccination Considering Late Onset Asthma. *Pediatr Infect Dis J* 2016; **35**: e275-284.

25 Ramos GFP, Kuiper S, Dompeling E, *et al.* Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children. *BMC Med Res Methodol* 2011; **11**: 150.

26 Ramos GFP, van Asselt ADI, Kuiper S, *et al.* Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model. *Eur J Health Econ HEPAC Health Econ Prev Care* 2014; **15**: 869–83.

27 Subbarao P, Mandhane PJ, Sears MR. Asthma: epidemiology, etiology and risk factors. *CMAJ Can Med Assoc J J Assoc Medicale Can* 2009; **181**: E181-190.

28 Bell CM, Urbach DR, Ray JG, *et al.* Bias in published cost effectiveness studies: systematic review. *BMJ* 2006; published online Feb 22. DOI:10.1136/bmj.38737.607558.80.